Literature DB >> 22570038

Multiple cavitary pulmonary nodules in association with pyoderma gangrenosum: case report.

Maraya de Jesus Semblano Bittencourt1, Luciana Fontenele Brito Soares, Lilia Sampaio Lobato, Alexandre Dias Mançano, Helandro Stuart Castro Leandro, Diana Mendes da Fonseca.   

Abstract

Pyoderma gangrenosum is a rare neutrophilic disease of unknown origin that is associated with systemic diseases in 50% of cases. It is characterized by erythematous-violaceous nodular lesions that quickly progress to painful ulcers, with undermined edges, necrotic-hemorrhagic, varying in size and depth, located mainly in the lower limbs. Extracutaneous locations of pyoderma gangrenosum are rare, usually involving the lungs; the main differential diagnosis in these cases is Wegener granulomatosis. We report a case of pyoderma gangrenosum, which showed multiple cavitary lung nodules, with good response to high doses of steroids. Once excluded the possibility of Wegener granulomatosis, the authors concluded that it was the manifestation of systemic pyoderma gangrenosum with pulmonary involvement.

Entities:  

Mesh:

Year:  2012        PMID: 22570038     DOI: 10.1590/s0365-05962012000200018

Source DB:  PubMed          Journal:  An Bras Dermatol        ISSN: 0365-0596            Impact factor:   1.896


  3 in total

1.  [Multiple abscesses after a cruise along the Latin American coast].

Authors:  C Reynolds; N Schofer; E Zengin; A W Lohse; S Faiss; S Schmiedel
Journal:  Internist (Berl)       Date:  2016-03       Impact factor: 0.743

2.  Pyoderma gangrenosum with renal and splenic impairment--case report.

Authors:  Luciana Rabelo de Carvalho; Virgínia Vinha Zanuncio; Bernardo Gontijo
Journal:  An Bras Dermatol       Date:  2013 Nov-Dec       Impact factor: 1.896

3.  A case of persistent fever, cutaneous manifestations and pulmonary and splenic nodules: clinical experience and a literature review.

Authors:  Ping Xu; Yazhou Cai; Xiaona Ying; Shiqiao Shi; Weidong Song
Journal:  Intern Med J       Date:  2019-02       Impact factor: 2.048

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.